Skip to content

CLINICAL studies

Servier clinical trials

We believe that in order to develop medicines that better meet patient needs, we need to involve them in the process as early as possible, right from the R&D stage, either directly or through patient organizations.

Integrating the patient into every stage of R&D leads to closer ties between basic and clinical research, giving rise to what is known as translational research.

In this way, patients play a fundamental role in the process of developing new treatments.

Photo of a Servier researcher
Photo of a Servier researcher

Understanding translational medicine

Translational medicine takes a multi-disciplinary approach involving researchers, clinicians and patients, and forms a major component in clinical research and development.

Harnessing digital technology to speed up the research process

At Servier, digital technology and data increase agility and efficiency to speed up the research process, the identification procedure and clinical trials. They are an essential component of our R&D and develop a more detailed understanding of patients.

SCORE is the digitalization program for our clinical trials. It encourages remote dialogue between patients and medical and scientific teams by enabling them to access data in real time. The goal? To facilitate decision-making.

Five principles of transparency

The Servier Group complies with the five principles of transparency set out by the European Federation of Pharmaceutical Industries and Associations (EFPIA) for clincial trials.

  1. Researchers are given access to our clinical data on all new medicines sold on the European and US market, through our data request platform. The platform also covers new indications authorized.
  2. We register our clinical trials involving human subjects on public registers, and we have published the results of our trials since 2004.
  3. We are committed to communicating summaries of our findings to the wider public in a language they can understand.
  4. We publish the results of phase III clinical trials in scientific literature, whether they are positive or negative.
  5. We certify that we have put in place procedures to apply these principles throughout the Servier Group.

100%

Servier publishes 100% of results from clinical trials carried out in Europe on the European Union Clinical Trials Register (EUCTR) website.

Our clinical development centers

Servier boasts a network of 15 clinical development centers, which are organized into three hubs in the North and South America, Europe and Asia-Pacific. They conduct local clinical trials in the Group’s therapeutic areas. They are operated by teams of highly qualified Servier employees.

Real-world studies

At Servier, we conduct real-world studies in all our therapeutic areas.

The aim of these studies is to enhance medical knowledge, as well as patient and doctor experiences. This is “real-life data,” reflecting the actual day-to-day lives of patients and health care professionals: the delivery of health care, management, and the impact of disease and treatment on daily life. This data is complementary to the data collected by interventional clinical studies.

By providing robust, additional analyses on the experience people have of living with diseases and medical treatment, real-life studies expand therapeutic understanding.

Read the insight: The importance of real-world studies

Read the insight: The importance of real-world studies